Literature DB >> 34131259

Bioinformatic profiling identifies prognosis-related genes in the immune microenvironment of endometrial carcinoma.

Pu Cheng1,2, Jiong Ma3, Xia Zheng3, Chunxia Zhou3, Xuejun Chen3.   

Abstract

Endometrial carcinoma (EC) is a common malignancy of female genital system which exhibits a unique immune profile. It is a promising strategy to quantify immune patterns of EC for predicting prognosis and therapeutic efficiency. Here, we attempted to identify the possible immune microenvironment-related prognostic markers of EC. We obtained the RNA sequencing and corresponding clinical data of EC from TCGA database. Then, 3 immune scores based on the Estimation of STromal and Immune cells in MAlignant Tumor tissues using Expression data (ESTIMATE) algorithm were computed. Correlation between above ESTIMATE scores and other immune-related scores, molecular subtypes, prognosis, and gene mutation status (including BRCA and TP53) were further analyzed. Afterwards, gene modules associated with the ESTIMATE scores were screened out through hierarchical clustering analysis and weighted gene co-expression network analysis (WGCNA). Differentially expressed analysis was performed and genes shared by the most relevant modules were found out. KEGG pathway enrichment analysis was conducted to explore the biological functions of those genes. Survival analysis was carried out to identify prognostic immune-related genes and GSE17025 database was further used to confirm the correlation between immune-related genes and the ImmuneScore. The immune-related scores based on ESTIMATE algorithm was closely related to the immune microenvironment of EC. 3 gene modules that had the closest correlations with 3 ESTIMATE scores were obtained. 109 immune-related genes were preliminarily found out and 29 pathways were significantly enriched, most of which were associated with immune response. Univariate survival analysis revealed that there were 14 genes positively associated with both OS and PFS. Among which, 11 genes showed marked correlations with ImmuneScore values in GSE17025 database. Our current study profiled the immune status and identified 14 novel immune-related prognostic biomarkers for EC. Our findings may help to investigate the complicated tumor microenvironment and develop novel individualized therapeutic targets for EC.

Entities:  

Year:  2021        PMID: 34131259     DOI: 10.1038/s41598-021-92091-5

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  31 in total

Review 1.  Immunotherapy in ovarian, endometrial and cervical cancer: State of the art and future perspectives.

Authors:  Jole Ventriglia; Immacolata Paciolla; Carmela Pisano; Sabrina Chiara Cecere; Marilena Di Napoli; Rosa Tambaro; Daniela Califano; Simona Losito; Giosuè Scognamiglio; Sergio Venanzio Setola; Laura Arenare; Sandro Pignata; Chiara Della Pepa
Journal:  Cancer Treat Rev       Date:  2017-07-31       Impact factor: 12.111

2.  Expression of Immunomodulatory Molecules PD-1, PD-L1, and PD-L2, and their Relationship With Clinicopathologic Characteristics in Endometrial Cancer.

Authors:  Nuran Sungu; Melahat Yildirim; Raziye Desdicioglu; Özge Başaran Aydoğdu; Aydan Kiliçarslan; Hayriye Tatli Doğan; Aylin Kiliç Yazgan; Mesut Akyol; Fazli Erdoğan
Journal:  Int J Gynecol Pathol       Date:  2019-09       Impact factor: 2.762

3.  Multi-omics profiling reveals distinct microenvironment characterization of endometrial cancer.

Authors:  Yixuan Cai; Yue Chang; Yun Liu
Journal:  Biomed Pharmacother       Date:  2019-07-25       Impact factor: 6.529

4.  International Patterns and Trends in Endometrial Cancer Incidence, 1978-2013.

Authors:  Joannie Lortet-Tieulent; Jacques Ferlay; Freddie Bray; Ahmedin Jemal
Journal:  J Natl Cancer Inst       Date:  2018-04-01       Impact factor: 13.506

5.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.

Authors:  Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2018-09-12       Impact factor: 508.702

Review 6.  Resistance to chemotherapy and hormone therapy in endometrial cancer.

Authors:  Parvesh Chaudhry; Eric Asselin
Journal:  Endocr Relat Cancer       Date:  2009-02-03       Impact factor: 5.678

7.  Long-term survival of endometrioid endometrial cancer patients.

Authors:  Leszek Gottwald; Piotr Pluta; Janusz Piekarski; Michał Spych; Katarzyna Hendzel; Katarzyna Topczewska-Tylinska; Dariusz Nejc; Robert Bibik; Jerzy Korczyński; Aleksandra Ciałkowska-Rysz
Journal:  Arch Med Sci       Date:  2010-12-29       Impact factor: 3.318

Review 8.  Epidemiology of gynecologic cancers in China.

Authors:  Xiyi Jiang; Huijuan Tang; Tianhui Chen
Journal:  J Gynecol Oncol       Date:  2018-01       Impact factor: 4.401

9.  A novel lncRNA-focus expression signature for survival prediction in endometrial carcinoma.

Authors:  Meng Zhou; Zhaoyue Zhang; Hengqiang Zhao; Siqi Bao; Jie Sun
Journal:  BMC Cancer       Date:  2018-01-05       Impact factor: 4.430

Review 10.  Immunotherapy in endometrial cancer: new scenarios on the horizon.

Authors:  Chiara Di Tucci; Carmela Capone; Giulia Galati; Valentina Iacobelli; Michele C Schiavi; Violante Di Donato; Ludovico Muzii; Pierluigi Benedetti Panici
Journal:  J Gynecol Oncol       Date:  2019-05       Impact factor: 4.401

View more
  1 in total

Review 1.  Natural Kinase Inhibitors for the Treatment and Management of Endometrial/Uterine Cancer: Preclinical to Clinical Studies.

Authors:  Rajeev K Singla; Sahar Behzad; Johra Khan; Christos Tsagkaris; Rupesh K Gautam; Rajat Goyal; Hitesh Chopra; Bairong Shen
Journal:  Front Pharmacol       Date:  2022-02-21       Impact factor: 5.810

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.